Eosinophilic Leukemia
📧 Sign up to get email alerts when something new happens for Eosinophilic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia [Phase 1]
Phase 1 clinical trial update for IL-5 CAR-T cell therapy in refractory/relapsed eosinophilic leukemia; the study is currently recruiting.
-
FDA approval · 2023-08-16FDA Approved: IMATINIB — Supplemental Application (Dr.Reddy's Laboratories Inc)
FDA approved a supplemental application for Imatinib from Dr. Reddy's Laboratories Inc, resulting in regulatory approval for a change to the…
-
FDA approval · 2020-01-09FDA Approved: IMATINIB MESYLATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for imatinib mesylate from Teva Pharmaceuticals USA, Inc., under ANDA204285.
-
FDA approval · 2016-08-04FDA Approved: IMATINIB MESYLATE — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approval of Teva's Imatinib Mesylate Original Application under ANDA204285 for a generic Imatinib product.
-
CLINICAL_TRIALS research · 2016-05-19Clinical Trial Update: Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia
A completed pediatric AML biomarker study update from the Children's Oncology Group examining biomarkers in bone marrow from high-risk AML p…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-12-03FDA Approved: IMATINIB MESYLATE — Original Application (BluePoint Laboratories)
FDA approved the original application for Imatinib Mesylate from BluePoint Laboratories (ANDA078340), authorizing a generic version of the c…
-
CLINICAL_TRIALS trial_result · 2015-04-15Clinical Trial Update: Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase [Phase 1]
This update summarizes a Phase 1 study of tipifarnib and bortezomib in patients with acute leukemia and blast-phase chronic myeloid leukemia…
-
EMA safety_alert · 2014-10-24European Medicines Agency recommends further measures to minimise risk of blood vessel blockage with Iclusig
EMA recommends additional measures to reduce the risk of blood vessel blockage with Iclusig (ponatinib), a cancer medicine, to improve patie…
-
CLINICAL_TRIALS trial_result · 2014-05-21Clinical Trial Update: 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia [Phase 2]
Phase 2 trial evaluating the combination of Triapine (3-AP) and fludarabine in various myeloproliferative disorders and advanced phases of c…
-
CLINICAL_TRIALS trial_result · 2013-02-08Clinical Trial Update: XK469R in Treating Patients With Refractory Hematologic Cancer [Phase 1]
Phase 1 trial update reporting initial safety and tolerability findings for XK469R in patients with refractory hematologic cancers.
-
FDA approval · 2013-01-25FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for GLEEVEC (imatinib mesylate) submitted by Novartis, reflecting changes to the product labeling.
-
CLINICAL_TRIALS trial_result · 2013-01-24Clinical Trial Update: Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 2]
Phase 2 trial of idarubicin and cytarabine with or without bevacizumab for newly diagnosed acute myeloid leukemia was terminated.
-
CLINICAL_TRIALS trial_result · 2012-03-13Clinical Trial Update: Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. [Phase 1]
A pediatric pharmacokinetic study of Glivec/Gleevec (imatinib) in children aged 1 to less than 4 with chronic myeloid leukemia, Philadelphia…
-
CLINICAL_TRIALS trial_result · 2010-12-29Clinical Trial Update: Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes [Phase 2]
A Phase 2 clinical trial evaluated the efficacy of imatinib mesylate in hypereosinophilic syndromes and has completed, reporting efficacy si…
-
CLINICAL_TRIALS research · 2009-09-15Clinical Trial Update: Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias [Phase 2]
This entry outlines a Phase 2 study evaluating imatinib (STI571) in patients with hypereosinophilic syndrome and eosinophilic leukemias, wit…
-
FDA approval · 2008-12-19FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for GLEEVEC (imatinib mesylate) from Novartis Pharmaceuticals Corporation, resulting in regulatory a…